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In vitro, b-amyloid (Ab) peptides form polymorphic
fibrils, with molecular structures that depend on
growth conditions, plus various oligomeric and pro-
tofibrillar aggregates. Here, we investigate structures
of human brain-derived Ab fibrils, using seeded fibril
growth from brain extract and data from solid-state
nuclear magnetic resonance and electron micro-
scopy. Experiments on tissue from two Alzheimer’s
disease (AD) patients with distinct clinical histories
showed a single predominant 40 residue Ab (Ab40)
fibril structure in each patient; however, the struc-
tures were different from one another. A molecular
structural model developed for Ab40 fibrils from
one patient reveals features that distinguish in-vivo-
from in-vitro-produced fibrils. The data suggest
that fibrils in the brain may spread from a single
nucleation site, that structural variations may
correlate with variations in AD, and that structure-
specific amyloid imaging agents may be an impor-
tant future goal.
INTRODUCTION
Aggregation of b-amyloid (Ab) peptides in brain tissue is the likely
cause of Alzheimer’s disease (AD) (Tanzi and Bertram, 2005;
Yankner and Lu, 2009). The most abundant Ab aggregates in
AD brain tissue are amyloid fibrils, the end point of the aggrega-
tion process, which are contained in neuritic plaques, diffuse
amyloid, and vascular amyloid. A variety of other aggregates
have also been identified, including Ab protofibrils and soluble
oligomers of various sizes. In vitro structural studies, using
solid-state nuclear magnetic resonance (NMR) (Benzinger
et al., 1998; Bertini et al., 2011; Lansbury et al., 1995; Paravastu
et al., 2008; Petkova et al., 2005, 2006; Qiang et al., 2011), elec-
tron microscopy (Goldsbury et al., 2005; Meinhardt et al., 2009;
Zhang et al., 2009), and other techniques (Kheterpal et al., 2001;
Kodali et al., 2010; Lu¨hrs et al., 2005; Olofsson et al., 2007; To¨ro¨k
et al., 2002), show that Ab fibrils are highly polymorphic, with
molecular structures that depend on aggregation conditions.CDetailed structural models for fibrils formed in vitro have been
developed from experimental data, showing that fibril poly-
morphs can differ in specific aspects of peptide conformation
and interresidue interactions, as well as overall structural sym-
metry (Bertini et al., 2011; Lu¨hrs et al., 2005; Paravastu et al.,
2008; Petkova et al., 2006). Studies of certain nonfibrillar (Ahmed
et al., 2010; Chimon et al., 2007; Lopez del Amo et al., 2012) and
protofibrillar (Qiang et al., 2012; Scheidt et al., 2011) Ab aggre-
gates, also formed in vitro, provide evidence for peptide confor-
mations similar to those in fibrils, but with reduced structural
order and different supramolecular organizations.
Molecular structures of Ab aggregates that develop in human
brain tissue have not been characterized in detail but evidence
exists that structural variations may be biomedically important:
(1) Structurally distinct fibrils can have different levels of toxicity
in neuronal cell cultures (Petkova et al., 2005); (2) Propagation of
exogenous Ab amyloid within transgenic mouse brains depends
on the source of the exogenous Ab-containing material (Langer
et al., 2011; Meyer-Luehmann et al., 2006; Sto¨hr et al., 2012);
(3) The binding stoichiometry of amyloid imaging agents, devel-
oped for positron emission tomography (PET), can differ sub-
stantially between Ab fibrils formed in vitro and fibrils in AD brain
tissue (Mathis et al., 2003). A precedent for the importance of
molecular structural variations in a neurodegenerative disease
is provided by transmissible spongiform encephalopathies
(TSEs), in which variations in the molecular structures of
mammalian prion protein (PrP) aggregates within brain tissue
produce distinct, self-propagating TSE ‘‘strains’’ (Bessen and
Marsh, 1994; Safar et al., 1998; Sto¨hr et al., 2012). Analogous
variations in the molecular structures of yeast prion fibrils pro-
duce prion strains in yeast (Toyama and Weissman, 2011).
Solid-state NMR has been an especially powerful structural
probe of Ab aggregates formed in vitro (Ahmed et al., 2010; Ben-
zinger et al., 1998; Bertini et al., 2011; Chimon et al., 2007; Lans-
bury et al., 1995; Lopez del Amo et al., 2012; Paravastu et al.,
2008; Petkova et al., 2005, 2006; Qiang et al., 2012, 2011;
Scheidt et al., 2011). Since solid-state NMR measurements
require milligram-scale quantities of 15N- and 13C-labeled fibrils,
direct measurements on Ab aggregates from brain tissue are not
possible. However, in vitro studies show that Ab fibrils grown
from seeds (i.e., short fibril fragments, produced by sonication
of existing fibrils) retain the molecular structures of the seeds
(Kodali et al., 2010; Paravastu et al., 2008; Petkova et al.,ell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc. 1257
2005). Thus, if amyloid-containing material is extracted from
brain tissue and used as the source of seeds, seeded fibril
growth can be used to amplify and label structures that develop
in the human brain (Paravastu et al., 2009).
In this paper, we describe studies of fibril structures from brain
tissue of two AD patients (patients I and II) with distinct clinical
histories and neuropathology, using simplified amyloid extrac-
tion and seeding protocols. Solid-state NMR and electronmicro-
scopymeasurements on 40 residue Ab (Ab40) fibrils seeded with
extract from two brain regions of patient I and three brain regions
of patient II indicate that each patient developed a single
predominant fibril structure. However, the predominant struc-
tures from the two patients are clearly different, as indicated
by both NMR chemical shifts and fibril morphologies in electron
microscopy. We develop a full molecular structural model for
Ab40 fibrils from patient I, which represents the first detailed,
experimentally determined structure of any brain-derived Ab
aggregate.
Given that Ab aggregation is inherently polymorphic, the struc-
tural specificity of brain-seeded Ab40 fibrils indicated by our data
is remarkable. Possible implications for processes by which
fibrils develop within the human brain, for the role of Ab fibrils
and the significance of their structures in AD, and for future
developments of structure-specific imaging agents and aggre-
gation inhibitors are discussed below.
RESULTS
A Single Predominant Ab40 Fibril Structure from
Patient I
Patient I, a female who died at age 72, had tentative clinical diag-
noses of Lewy body dementia (LBD) and primary progressive
aphasia. Autopsy revealed neuritic Ab plaques, diffuse amyloid,
neurofibrillary tangles, and mild atrophy of frontal and parietal
lobes indicative of AD, but few Lewy bodies. Starting with 1 g
of tissue that contains abundant plaques (Figure 1A), our amyloid
extraction protocol (see Extended Experimental Procedures)
produced approximately 10 mg of amyloid-enriched material.
Fibril fragments in this material were visible by transmission elec-
tron microscopy (TEM) (Figure 1B). After addition of 0.8 mg of
synthetic 15N,13C-labeled Ab40, long fibrils developed within
several hours (Figures 1C and 1D). The fibrils have constant
apparent diameters of 7 ± 1 nm, do not self-associate into thicker
bundles, and appear morphologically homogeneous. Fibrils
seeded with extract from occipital lobe tissue (Figures 1C and
1D) are indistinguishable from fibrils seeded with extract from
temporal/parietal lobe tissue (Figure 1E). Brain-seeded fibrils
from patient I are morphologically distinct from ‘‘striated ribbon’’
and ‘‘twisted’’ Ab40 fibrils grown in vitro (without brain material)
in our laboratory (Paravastu et al., 2008), as well as in vitro fibrils
described by others (Goldsbury et al., 2005; Kodali et al., 2010;
Meinhardt et al., 2009).
Control experiments, detected by thioflavin T fluorescence
and by TEM, showed rapid fibril growth when brain tissue from
AD patients was used, but not when identical experiments
were performed with non-AD tissue (Figure S1 available online).
Thus, seeding of fibril growth is attributable to fibrils in the AD
brain tissue, not to other components of brain tissue that survive1258 Cell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc.the extraction protocol. Compared with protocols described
previously (Paravastu et al., 2009), our current protocols involve
fewer extraction steps, preserve more components of the brain
tissue, and permit NMR samples to be created in a single seed-
ing step from smaller quantities of tissue.
Two-dimensional (2D) solid-state NMR spectra of Ab40 fibrils
seeded with extract of occipital lobe tissue (Figures 1F and 1G)
show remarkably sharp cross-peak signals, with a single set of
15N and 13C NMR chemical shifts for each 15N,13C-labeled resi-
due (0.7–1.2 ppm and 1.3–1.8 ppm FWHM linewidths for 13C and
15N signals, respectively). Because chemical shifts are exqui-
sitely sensitive tomolecular structural variations, the observation
of a single set of shifts implies a single predominant fibril struc-
ture, consistent with the morphological homogeneity in TEM
images. Two-dimensional spectra of fibrils seeded with extract
of temporal/parietal lobe tissue (Figures 1H and 1I; Figure S2F)
are nearly identical, apart from differences in signal-to-noise ra-
tio due to differences in sample sizes. Chemical shifts in spectra
of these brain-seeded fibrils are significantly different from shifts
reported previously for fibrils grown in vitro (Bertini et al., 2011;
Paravastu et al., 2008; Petkova et al., 2005). The high signal-
to-noise ratio in Figure 1F allows us to place an upper limit of
10% on the mass of minor structural components relative to
the predominant fibril structure in the occipital-seeded sample.
Different Ab40 Fibril Structures from Brain Tissue of
Patients I and II
Patient II, a female who died at age 80, had a clinical diagnosis of
probable AD. Autopsy revealed severe AD, including gross atro-
phy of the brain, loss of neurons, gliosis in the hippocampus and
cortex, neurons with granulovacuolar degeneration and Hirano
bodies, neuritic plaques, and neurofibrillary tangles. Brain-
seeded Ab40 fibrils prepared from occipital lobe (Figures 2A
and 2B) and frontal lobe (Figure 2C) tissue of patient II show an
apparent periodic twist in TEM images (minima and maxima in
apparent width approximately equal to 11 nm and 5 nm; 85 ±
10 nm distance between minima) that is absent from images of
fibrils from patient I (Figures 1C–1E). Solid-state NMR spectra
again show a single set of chemical shifts, indicating a single pre-
dominant fibril structure that is the same in samples seeded with
occipital lobe, frontal lobe, or temporal lobe tissue (Figures 2D–
2G, S2G, and S2H) However, chemical shifts for brain-seeded
fibrils from patients I and II are obviously different (Figures 2D
and 2E). Signals with the chemical shifts of fibrils from patient I
are undetectable in spectra of fibrils from patient II, and vice
versa. These data indicate that patients I and II developed struc-
turally distinct fibrils in their brains.
From the 2D spectrum in Figure 2D, the mass of any minor
structural components must be less than 10% relative to the pre-
dominant fibril structure. Although the twisted morphology in
TEM images of fibrils derived from brain tissue of patient II is
similar to the morphology of certain Ab40 fibrils grown in vitro
(Paravastu et al., 2008), the NMR chemical shifts are significantly
different (Figure S6).
Structural Model for Ab40 Fibrils from Patient I
The high quality of 2D solid-state NMR spectra of Ab40 fibrils
derived from brain tissue of patient I encouraged us to pursue
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Figure 1. Evidence for a Single Predominant
Ab40 Fibril Structure in Brain Tissue of
Patient I
(A) Light microscope image of cortical tissue from
patient I, with immunohistochemical staining for
b-amyloid using monoclonal antibody 6E10.
Amyloid deposits are red or pink.
(B) Negatively stained TEM image of extract from
occipital lobe tissue before addition of monomeric
Ab40. Fibril fragments are circled in red.
(C and D) TEM images of isotopically labeled Ab40
fibrils, recorded 24 hr after addition of monomeric
Ab40 to sonicated extract from occipital lobe tis-
sue. Ab40 was uniformly 15N,13C-labeled at F19,
V24, G25, A30, I31, L34, and M35.
(E) TEM image of fibrils prepared by seeding with
sonicated extract from temporal/parietal lobe
tissue.
(F and G) 2D 13C-13C and 15N-13C solid-state NMR
spectra of Ab40 fibrils, seeded with extract from
occipital lobe tissue. Black lines and labels show
site-specific cross-peak assignments.
(H and I) 2D 13C-13C and 15N-13C solid-state NMR
spectra of Ab40 fibrils, seeded with extract from
temporal/parietal lobe tissue, with the same black
lines as in (F) and (H).
See also Figures S1 and S2.a full molecular structure determination. We prepared fibril sam-
ples with a variety of isotopic labeling patterns (Table 1). A uni-
formly 15N,13C-labeled sample (sample A) was generated by
seeding recombinant Ab40 with extract from occipital lobe tis-
sue. Samples with other labeling patterns (samples C–G) were
generated by seeding synthetic Ab40 with aliquots of samples
whose spectra appear in Figure 1 (sample B). NMR chemicalCell 154, 1257–1268, Sepshifts are consistent in 2D spectra of all
samples (Figures 3 and S2), indicating
that all samples contained the same fibril
structure.
From 2D and 3D NMR spectra, we
obtained unique assignments of all 15N
and 13C chemical shifts (Table S1). As
shown in Figure 3, all residues in the
Ab40 sequence contribute strong and
sharp signals to the solid-state NMR
spectra, except H14 and E22. Because
dynamically disordered segments of a
protein assembly are generally absent
from such solid-state NMR spectra
and statically disordered segments yield
broad signals, it appears that the
entire Ab40 sequence participates in the
ordered and relatively rigid molecular
structure.
We obtained structural restraints from a
combination of solid-state NMR and elec-
tron microscopy measurements. Struc-
tural restraints from solid-state NMR,
summarized in Table S2, include: (1)conformation-dependent 13Cand 15Nchemical shifts (Figure 4A),
from which backbone torsion angle predictions (Table S1) were
derived using the TALOS+ program (Shen et al., 2009); (2) inter-
molecular 13C-13C magnetic dipole-dipole couplings, measured
with the PITHIRDS-CT technique (Tycko, 2007), which imply an
in-register parallel b sheet structure (Figure 4B); (3) 15N-13C
dipole-dipole couplings between K28 N
ε
and D23 Cg sites,tember 12, 2013 ª2013 Elsevier Inc. 1259
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Figure 2. Evidence for Different Ab40 Fibril
Structures in Brain Tissue of Patients I and II
(A and B) TEM images of Ab40 fibrils, recorded
36 hr after addition of monomeric Ab40 to soni-
cated extract from occipital lobe tissue of
patient II. Blue arrows indicate minima in the
apparent fibril diameter, associated with a periodic
twist that is absent from fibril images in Figure 1.
Ab40 was uniformly 15N,13C-labeled at F19, V24,
G25, S26, A30, I31, L34, and M35.
(C) TEM image of fibrils prepared by seeding with
sonicated extract from frontal lobe tissue of
patient II.
(D and E) 2D 13C-13C and 15N-13C solid-state NMR
spectra of Ab40 fibrils, seeded with extract from
occipital lobe tissue of patient II (blue contours) or
patient I (red contours). Black lines and labels
show site-specific cross-peak assignments for
spectra from patient II.
(F and G) 2D 13C-13C and 15N-13C solid-state NMR
spectra of Ab40 fibrils, seeded with extract from
frontal lobe tissue of patient II, with the same black
lines as in (D) and (E).
See also Figures S2 and S6.measured with the fsREDOR technique (Jaroniec et al., 2001),
which indicate a 0.35 ± 0.02 nm distance, consistent with a
D23-K28 salt bridge (Figure 4C). (4) intramolecular dipole-dipole
couplings among backbone amide 15N nuclei and among
backbone carbonyl 13C nuclei, measured with the 15N-BARE
and 13C-BARE techniques (Hu et al., 2012), which serve as
site-specific restraints on backbone conformation (Figures 4D
and S3); (5) interresidue distance restraints from 2D RAD
(Morcombe et al., 2004; Takegoshi et al., 2001), PAR (De Pae¨pe
et al., 2008), band-selective fpRFDR (Bayro et al., 2009; Ishii,
2001), and band-selective TEDOR (Jaroniec et al., 2002) spectra
(Figure S4 and Table S3).
Dark-field TEM images of unstained samples (Figure 4E)
allow quantification of the mass-per-length (MPL) of individual
fibrils (Chen et al., 2009; Goldsbury et al., 2005). Given that1260 Cell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc.amyloid fibrils contain cross-b structural
motifs with a 0.47–0.48 nm intermolec-
ular distance along the fibril axis
(supported by Figure 4B) and that the
molecular weight of Ab40 is 4.3 kDa, a
single cross-b unit would have MPL
9.0 kDa/nm. The observed MPL value
of 28 ± 2 kDa/nm (Figure 4F), together
with the observation of a single set of
NMR chemical shifts for all residues,
implies a molecular structure comprised
of three cross-b units, with 3-fold sym-
metry about the long-fibril axis.
Structure calculations were performed
with the Xplor-NIH program (Schwieters
et al., 2006), starting from nine well-
separated Ab40 molecules with random
conformations. In addition to distance
and conformational restraints from theNMR data, rotational and translational symmetry restraints
were applied, as dictated by the MPL data, the solid-state
NMR spectra, and the fibrillar nature of the Ab40 assemblies.
Low-energy final structures consist of three copies of a
3-fold-symmetric repeat unit, with translational symmetry along
the fibril axis.
Figure 5A shows the repeat unit from the final structure with
the lowest total restraint energy. Repeat units from 20 low-
energy structures (PDB code 2M4J) are superimposed in
Figure 5B. This bundle of structures represents the full range of
final structures that are fully consistent with the experimental
data, defined by the absence of violations of backbone torsion
angle predictions exceeding 7, the absence of violations of dis-
tance restraints exceeding 0.06 nm, and good agreement with
the 15N- and 13C-BARE data (Figure S3). Structure calculation
Table 1. Summary of Isotopic Labeling Patterns and Solid-State NMR Measurements on Ab40 Fibrils Derived from Patient I
Sample Uniformly 15N,13C-Labeled Residues Selectively 13C-Labeled Sites NMR Measurementsa
A residues 1–40 2D fpRFDR, NCAX, NCOCX, RAD, PAR, and TEDOR;
3D NCACX and NCOCX; 15N- and 13C-BARE
B F19, V24, G25, A30, I31, L34, M35 2D fpRFDR, RAD, NCACX
C F20, D23, V24, K28, G29, A30, I31 2D fpRFDR, RAD, NCACX; fsREDOR
D H14, Q15, A21, V36, G37 2D fpRFDR, RAD, NCACX; 15N- and 13C-BARE
E K16, F19, A21, E22, I32, V36 2D fpRFDR, RAD, NCACX; 15N- and 13C-BARE
F A2 and A21 methyl; V12, F20, I31,
G38 carbonyl
PITHIRDS-CT
G A30 methyl, V18 carbonyl PITHIRDS-CT
aThe following abbreviations are used: fpRFDR, finite-pulse radio-frequency-driven recoupling; NCACX, 15N-13Ca-
13Cx chemical shift correlation;
NCOCX, 15N-13CO-13Cx chemical shift correlation; RAD, radio-frequency-assisted diffusion; PAR, proton-assisted recoupling; TEDOR, transferred
echo double resonance; BARE, backbone recoupling; fsREDOR, frequency-selective rotational echo double resonance; PITHIRDS-CT, constant-
time p-pulse recoupling.statistics appear in Table S4. Figures 5C and 5D show an ideal-
ized representation of the full fibril structure.
Attempts to calculate structures with 2-fold rotational symme-
try, using the same set of experimental restraints and the same
Xplor-NIH protocols, produced no final structures that were fully
consistent with the experimental data.
Key distance restraints for the bundle of structures in Figure 5B
include intramolecular V24-K28, K28-I31, E11-V39, M35-G38,
M35-V39, M35-V40, F19-L34, and H13-V39 distances, as well
as intermolecular F4-V24, R5-V24, D7-S26, S8-V24, A30-V40,
and I32-V39 distances (see Figure S4 and Table S3). I31-V39,
H13-V40, L17-I32, and F19-I32 contacts, observed in 3-fold-
symmetric fibrils formed in vitro (Paravastu et al., 2008), are
not present in Ab40 fibrils from patient I.
Further support for the structure in Figure 5 comes from two
additional experiments. First, we used 2D 15N-13C solid-state
NMR spectra to monitor site-specific hydrogen/deuterium
(H/D) exchange rates during exposure of sample A to D2O buffer
(Figure 6). Only backbone amide sites of A2, F4, D7, S8, G9,
G25, and S26, which are colocalized in the structure, exhibited
significant H/D exchange over an 18 day period. These results
suggest that the N-terminal segment undergoes transient
unfolding events that also expose G25 and S26. (Continual
large-amplitude motions are ruled out by NMR signal strengths
and dipole-dipole couplings in Figures 3, 4B, and S3.) Second,
we measured site-specific enhancements of 15N spin-lattice
relaxation rates induced by paramagnetic CuNa2-EDTA (Fig-
ure S5). The smallest relaxation enhancements were observed
for residues 30–40, consistent with their burial in the fibril core
and with a narrow central pore that excludes the Cu-EDTA
complex.
Comparison with In Vitro Fibril Structures
In-register parallel intermolecular alignment (Figures 5C and 5D)
also occurs in full-length Ab fibrils formed in vitro without brain
material (Benzinger et al., 1998; Lu¨hrs et al., 2005; Paravastu
et al., 2008; Petkova et al., 2005; To¨ro¨k et al., 2002), although
metastable intermediates (Qiang et al., 2012) and fibrils formed
by certain Ab fragments (Colletier et al., 2011; Lansbury et al.,
1995) can contain antiparallel cross-bmotifs. Three-fold symme-Ctry occurs in certain in vitro Ab40 fibrils with ‘‘twisted’’ morphol-
ogies (Goldsbury et al., 2005; Paravastu et al., 2008). (Figure 5E),
whereas other in vitro Ab40 and Ab42 fibrils exhibit 2-fold sym-
metry (Bertini et al., 2011; Meinhardt et al., 2009; Petkova
et al., 2006; Zhang et al., 2009) (Figure 5F). D23-K28 salt bridge
interactions have been observed in 2-fold-symmetric (Petkova
et al., 2006), but not 3-fold-symmetric (Paravastu et al., 2008),
Ab40 fibrils formed in vitro. Residues 12–19 form a b strand in
all known Ab40 structures, with sidechains of even-numbered
residues exposed on the exterior surface, whereas residues
30–40 are buried in the fibril core. Close contacts between F19
and L34 sidechains occur in both in vitro Ab40 (Bertini et al.,
2011; Paravastu et al., 2008; Petkova et al., 2006) and in vitro
Ab42 (Ahmed et al., 2010) fibrils.
Novel conformational features in Ab40 fibrils frompatient I may
provide a basis for the development of structure-specific inhibi-
tors or imaging agents. These features include a twist in residues
19–23 that allows sidechains of either F20 or E22 to be buried
within the structure, a kink at G33 that allows sidechains of I32
and L34 to point in opposite directions and make contacts with
different sets of Ab40 molecules, and a bend in glycine residues
37 and 38. In contrast, fibrils formed in vitro by Ab40 and Ab42
contain relatively simple strand-bend-strand conformations, as
in Figures 5E and 5F. A variety of experiments indicate N-termi-
nal disorder in in vitro Ab40 and Ab42 fibrils (Kheterpal et al.,
2001; Lu¨hrs et al., 2005; Paravastu et al., 2008; Petkova et al.,
2005). However, Ab40 fibrils from patient I exhibit strong, sharp
NMR signals (Figure 3) and strong 13C-13C and 15N-15N dipole-
dipole couplings for N-terminal residues (Figures 4B and S3),
indicating structural order.
MPL data for Ab40 fibrils from patient II also indicate 3-fold
symmetry (Figure 4H). F19-L34 sidechain contacts, which are
clear in spectra of samples A and B from patient I (Figure S4C),
are not detected in fibrils from patient II. From chemical
shifts (Figure S6), TALOS+ predicts a continuous b strand in
residues 28–32 in fibrils from patient II, whereas structures in
Figure 5B have a non-b-strand conformation at G29. Thus,
fibrils from patients I and II differ in both peptide backbone
conformation and interresidue interactions, but not overall
symmetry.ell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc. 1261
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Figure 3. The Entire Ab40 Sequence Is Structurally Ordered in Fibrils from Patient I
(A and B) 2D solid-state 15N-13C NMR spectra of uniformly 15N,13C-labeled Ab40 fibrils. (A) A NCACX spectrum, correlating backbone 15N chemical shifts of a
given residue with 13C chemical shifts of the same residue. (B) A NCOCX spectrum, correlating backbone 15N chemical shifts of a given residue with 13C chemical
shifts of the previous residue. Only the aliphatic 13C regions are shown. Asterisks (B) denote intraresidue cross-peaks and cross-peaks involving sidechain 15N
signals.
(C) 2D 13C-13C spectrum, obtained with 50 ms RAD mixing (left) and 2.94 ms fpRFDR mixing (right). Black labels indicate CO/Ca (left) and Ca/Cb (right) cross-
peaks. Blue labels indicate additional intraresidue cross-peaks, including multiple-bond cross-peaks. Site-specific cross-peak assignments in these 2D spectra
show that residues 1–40 contribute relatively strong, sharp signals, implying structural order.
See also Table S1.DISCUSSION
Significance of Structural Observations
Polymorphism is an inherent property of Ab fibril formation
(Colletier et al., 2011; Goldsbury et al., 2005; Kodali et al.,
2010; Meinhardt et al., 2009; Paravastu et al., 2008; Petkova
et al., 2005; Qiang et al., 2011), attributable to the coexistence
of multiple nucleation processes (each leading to a different fibril
structure), the comparably high thermodynamic stabilities of
distinct polymorphs, and the low rates of dissociation of peptide
monomers or soluble species from fibrils (Qiang et al., 2013). It is
therefore surprising that Ab40 fibrils derived from brain tissue of
either patient I or patient II are not polymorphic. There are at least
three possible explanations. (1) The brain tissue environment1262 Cell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc.permits only one nucleation process. The observation of distinct
fibril structures from patients I and II contradicts this explanation
unless unknown differences in their brain tissue selected
different nucleation processes. (2) Multiple fibril structures are
nucleated, and all but one are eliminated by amyloid clearance
mechanisms. Unknown differences in clearance mechanisms
between patients I and II would be required to account for our
data. (3) The majority of fibrils that persist to the time of death
arise from nucleation of one structure at a single site. This
structure then spreads by physical or biologically-mediated
processes of fragmentation and transport, possibly involving
activated microglia (Majumdar et al., 2008). After transport to a
new site, fibril fragments serve as seeds for the growth of struc-
turally identical fibrils (Langer et al., 2011), as in the experiments
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Figure 4. Structural Restraints on Ab40
Fibrils from Patient I
(A) Residue-specific secondary 13CNMR chemical
shifts. Nonglycine residues with positive values for
Cb and negative values for CO and Ca are likely to
have b strand conformations. Open symbols indi-
cate glycine residues.
(B) Intermolecular 13C-13C dipole-dipole couplings
among 13C-labeled methyl sites of A2 or A21 or
13C-labeled carbonyl sites of V12, F20, I31, or G38.
Comparison with simulations for linear chains of
13C nuclei with various spacings indicates inter-
molecular distances of approximately 0.5 nm for
all labeled sites, implying in-register parallel
b sheets.
(C) 15N-13C dipole-dipole couplings between D23
Cg and K28 Nz sites indicate a 0.35 ± 0.02 nm
interatomic distance, implying salt-bridge in-
teractions between oppositely charged D23 and
K28 sidechains.
(D) 15N-15N dipole-dipole couplings among back-
bone amide nitrogens. Stronger couplings for F20
and A21 indicate non-b strand conformations.
(E) Dark-field TEM image of unstained fibrils.
Mass-per-length (MPL) values are obtained from
integrated intensities within 300 nm 3 50 nm
rectangles, centered on TMV (cyan) or Ab40
(yellow) fibril segments, after subtraction of the
average background intensity from similar rect-
angles on either side (dotted lines). TMV particles
serve as in situ MPL standards.
(F) MPL histogram, with light blue dashed lines
indicating MPL values expected for structures
comprised of 1–5 cross-b units. Dark blue line is a
best-fit Gaussian function, centered at 28.4 ±
0.3 kDa/nm, and with a full-width-at-half-
maximum (FWHM) equal to 12.0 ± 0.8 kDa/nm.
(G) Histogram of errors in MPL values due to noise
in the dark-field images. The best-fit Gaussian
function has FWHM equal to 12.8 ± 0.6 kDa/nm,
showing that random noise accounts for the
width in (F).
(H) MPL histogram for Ab40 fibrils seeded with
extract from occipital lobe tissue of patient II,
with best-fit Gaussian function centered at
29.1 ± 1.2 kDa/nm and FWHM equal to 12.1 ±
0.8 kDa/nm.
Error bars in (B), (C), and (D) are calculated from
the root-mean-squared (rms) noise in the corre-
sponding NMR spectra. See also Figures S3 and
Table S2.described above. In this scenario, differences between patients I
and II may be due entirely to the stochastic nature of the initial
nucleation event.
Patients I and II differed in clinical history (initial diagnoses of
LBD versus AD) and neuropathology (mild versus severe cortical
atrophy), although both patients developed Ab plaques and
neurofibrillary tangles characteristic of AD. The observation of
distinct Ab40 fibril structures from the two patients, both in
TEM images and in solid-state NMR spectra, suggests that
differences in fibril structure may correlate with differences inCdisease development. The analogy with TSE strains, in which
self-propagating polymorphisms of PrP aggregates lead to
distinct anatomical patterns of PrP deposition, disease incuba-
tion periods, and symptoms (Bessen and Marsh, 1994; Collinge,
2001; Safar et al., 1998), is obvious. Prior suggestive evidence for
AD strains includes the observation of polymorph-specific differ-
ences in Ab40 fibril toxicity in neuronal cell cultures (Petkova
et al., 2005) and the observation that propagation efficiencies
of exogenous Ab42 fibrils in transgenic mice depend on the
source of the exogeneous material (Meyer-Luehmann et al.,ell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc. 1263
Figure 5. Molecular Structure of Ab40
Fibrils from Patient I
(A) Structure with the lowest total experimental
restraint energy in Xplor-NIH calculations. The
3-fold-symmetric repeat unit is shown, as viewed
along the fibril growth axis. Backbone and
sidechain carbon atoms are gray and green,
respectively.
(B) Superposition of 20 structures that are
consistent with experimental restraints (PDB code
2M4J). Sidechains of the three Ab40 molecules in
the repeat unit are yellow, green, or orange.
(C and D) Two views of the idealized fibril struc-
ture, created by repeating the trimeric unit 18
times with 0.48 nm displacements along the
fibril axis.
(E and F) Structural models for Ab40 fibril poly-
morphs with 3-fold and 2-fold symmetry about the
fibril growth axis, developed previously from solid-
state NMR and electron microscopy measure-
ments on fibrils grown in vitro. Repeat units from
thesemodels are shown, calculated as regularized
averages of structure bundles in PDB codes 2LMP
and 2LMN, respectively.
See also Figures S4 and S6 and Tables S3 and S4.2006; Sto¨hr et al., 2012). Further experiments are certainly
required before AD strains can be considered a reality.
Role of Fibrils in AD
Both the identity of Ab aggregates that contribute most to neuro-
degeneration in AD and their pathogenic mechanisms are
currently uncertain (Yankner and Lu, 2009). Various experiments
point to nonfibrillar Ab oligomers as neurotoxic species (Krafft
and Klein, 2010; Lesne´ et al., 2006; Noguchi et al., 2009; Selkoe,
2008). Ongoing fibril growth or conversion of oligomers to fibrils
may be required for neurotoxicity (Jan et al., 2011). Although
mature amyloid fibrils are sometimes described as being
nontoxic in cell cultures, experiments by us (Petkova et al.,
2005; Qiang et al., 2012) and others (Chimon et al., 2007; Walsh
et al., 1999) show that Ab40 fibrils are indeed toxic in cell
cultures. In brain tissue, Ab fibrils may initiate inflammation
(Cameron and Landreth, 2010; Glass et al., 2010), oxidative
damage (Sultana et al., 2009; To˜ugu et al., 2011), or other path-
ogenic processes.1264 Cell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc.The severity of cognitive impairment in
AD patients prior to death has been re-
ported not to correlate with plaque den-
sity (Giannakopoulos et al., 1997). At least
one study reached the opposite conclu-
sion (Cummings et al., 1996); the quantity
of brain amyloid has been found to corre-
late with the likelihood of progression
from mild cognitive impairment to AD
(Villemagne et al., 2011). Although
asymptomatic elderly people develop
amyloid plaques, the quantity of amyloid
is generally less than in AD patients
(Aizenstein et al., 2008). Fibrillar oligo-mers (which may be fibril fragments), but not nonfibrillar oligo-
mers, have been reported to be elevated in AD patients (Tomic
et al., 2009).
Thus, Ab fibrils (along with oligomeric and protofibrillar
species) remain as likely causative or contributing agents in
AD. Our finding of specific fibril structures in AD patients sug-
gests that certain structures may be more pathogenic than
others. The weakness of correlations between total amyloid
deposition and cognitive deficiency in AD patients may be due
in part to differential effects of amyloid deposits comprised of
different fibril structures. Similarly, amyloid deposits in brain
tissue of asymptomatic elderly people may contain relatively
inert structures. It is also conceivable that specific fibril struc-
tures coexist with specific oligomer structures, for example if
the oligomers are ‘‘on-pathway’’ intermediates to fibril formation,
or if the oligomers are produced by degradation of fibrils. Asso-
ciation of specific Ab fibrils with AD may then arise indirectly,
through their association with specific oligomers. Structural
data for fibrils may then represent a window into the properties
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Figure 6. H/D Exchange Measurements on Ab40 Fibrils Derived from Occipital Lobe Tissue of Patient I, Detected through 2D 15N-13C Solid-
State NMR Spectra
(A) 2D NCA spectra of uniformly 15N,13C-labeled fibrils, before H/D exchange, after various periods of exchange, and after back-exchange. In all spectra, the
highest contour level is normalized to the strongest cross-peak, and 16 contour levels are shown, decreasing by successive factors of 1.2. In the spectrum at
426–437 hr, arrows indicate positions of resolved or partially resolved cross-peaks that show clear reductions in intensity due to H/D exchange.
(B) 2D NCACX spectra after various periods of exchange and after back-exchange, with contour levels as in (A).
(C) Structure from Figure 5A with residues that exhibit significant H/D exchange colored magenta.
See also Figure S5.of oligomers, whose molecular structures are particularly chal-
lenging to characterize directly. Further experiments are required
to test these possibilities.
Ab40 and Ab42
The 42 residue form of Ab (Ab42) is often considered particularly
important in AD, because of its more rapid aggregation kinetics
in vitro (Bitan et al., 2003; Jarrett et al., 1993), elevated levels in
patients with some disease-associated mutations (Scheuner
et al., 1996), and elevated levels in AD brain tissue (Kuo et al.,
1996). However, depending on experimental conditions, differ-
ences in aggregation kinetics in vitro are not large. Ab40 levels
in humans are still roughly 5-fold larger than Ab42 levels,
even with disease-associated mutations. Direct assessment of
Ab40/Ab42 ratios in Ab aggregates within brain tissue dependsCon monoclonal antibodies that recognize C-terminal epitopes
(Iwatsubo et al., 1994). For Ab40 fibrils with the structure in Fig-
ure 5A, the C terminus is not accessible to antibodies, suggest-
ing that such assessments may not be reliable. Measurements
on AD brain extract, after dissolution in formic acid, show a
wide range of Ab40/Ab42 ratios (Gravina et al., 1995).
In our hands, polymorphic Ab42 fibrils prepared in vitro do not
seed the growth of Ab40 fibrils. Therefore, our brain-seeded
Ab40 fibrils most likely arise from Ab40 fibrils (not Ab42 fibrils)
in the brain tissue of patients I and II.
Implications for Imaging Agents and Inhibitors
In vivo imaging of Ab amyloid by positron emission tomography,
based on compounds that bind preferentially to Ab fibrils (Clark
et al., 2011; Klunk et al., 2004), has become an important toolell 154, 1257–1268, September 12, 2013 ª2013 Elsevier Inc. 1265
in AD research and diagnosis. Existing imaging agents were
developed without detailed molecular structural information for
fibrils that develop in brain tissue. Specific structural differences
between brain-seeded and in vitro fibrils identified above may
facilitate the development of imaging agents with improved
specificity and structural selectivity.
Significant efforts have also been devoted to the development
of inhibitors of Ab aggregation, including both small-molecule
(Yang et al., 2005) and peptide-based (Gordon et al., 2001) inhib-
itors. Compounds that inhibit formation of the specific Ab struc-
tures that develop in AD brain tissue may be particularly valuable
in AD prevention or treatment.
EXPERIMENTAL PROCEDURES
Amyloid Extraction and Seeding
Amyloid-enriched extract was produced by subjecting brain tissue to homog-
enization, ultracentrifugation in 1.2 M and 1.9 M sucrose, DNase I digestion,
and a brief treatment with 1%sodiumdodecyl sulfate to remove residual lipids.
After washing, this material was pelleted and stored at 20C. Fibrils were
grown at 24C by adding synthetic or recombinant Ab40, solubilized in
dimethyl sulfoxide, to a 5 mg/ml suspension of sonicated brain extract in
10 mM phosphate buffer (pH 7.4), with a final Ab40 concentration of
100 mM. For solid-state NMR, fibrils (embedded in brain extract) were pelleted,
lyophilized, packed intomagic-angle spinning (MAS) rotors, and rehydrated by
addition of H2O. Full details are given in Extended Experimental Procedures.
Solid-State NMR and Electron Microscopy
NMRmeasurements were performed at magnetic field strengths of 9.4 T, 14.1
T, and 17.5 T using Varian Infinity and InfinityPlus spectrometers and triple-
resonance MAS probes from the group of Dr. Ago Samoson (Tallinn University
of Technology, Estonia) and from Varian. Full details are given in Extended
Experimental Procedures and Table S2.
TEM images of negatively stained and unstained samples were obtained
with an FEI Morgagni microscope, operating at 80 keV. Dark-field images for
MPL determination were obtained and analyzed as described previously
(Chen et al., 2009).
Structure Calculations
Three stages of simulated annealing within Xplor-NIH were used to arrive at
final structures that satisfy all experimental restraints, consisting of 15 distance
restraints per molecule from PITHIRDS-CT, fsREDOR, 15N-BARE, and 13C-
BARE data, 60 torsion angle restraints per molecule from TALOS+ predictions,
50 torsion angle potential surfaces per molecule from 15N-BARE and 13C-
BARE data, and 72 interresidue distance restraints per molecule from 2D
PAR, RAD, band-selective fpRFDR, and TEDOR spectra. Full details are given
in Extended Experimental Procedures and Table S4.
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